Stocks Health care TEVA
NYSE · Health careTeva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd brought in $14.1B of revenue over the twelve months to June 30, 2026, down 15.2% from a year earlier. Operating cash flow minus capital spending left $1.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $3.7B in cash against $4.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.
Watch TEVA in 60 secondsWhat Teva Pharmaceutical Industries Ltd does
Teva Pharmaceutical Industries develops, produces, and markets generic pharmaceuticals, active pharmaceutical ingredients, and specialty medicines. The company supplies prescription drugs, over-the-counter treatments, and sterile injectables to healthcare systems, pharmacies, and hospitals worldwide. Its shares trade on NYSE under the ticker TEVA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $17.3B | $1.4B | $1.21 | $1.1B |
| 2024 | $16.5B | -$1.6B | -$1.45 | $749M |
| 2023 | $15.8B | -$559M | -$0.50 | $842M |
| 2022 | $14.9B | -$2.4B | -$2.20 | $1B |
| 2021 | $15.9B | $417M | $0.38 | $236M |
| 2020 | $16.7B | -$4B | -$3.64 | $638M |
Full financial statements: income, balance sheet and cash flow
Where TEVA ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2019 | $0.00 | n/a | n/a |
| 2018 | $0.00 | $12M | n/a |
| 2017 | $0.85 | $901M | n/a |
| 2016 | $1.36 | $1.3B | 396% |
| 2015 | $1.36 | $1.2B | n/a |
| 2014 | $1.34 | $1.2B | n/a |
Latest SEC filings
What Teva Pharmaceutical Industries Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Material agreement8-KTeva subsidiaries issued multiple series of euro and US dollar senior notes to fund debt redemptions and general corporate purposes.
- September 14, 2026Other event 8-K
- September 14, 2026Form 8-A12B/A filing 8-A12B/A
- September 14, 2026Delisting notice 25-NSE
- September 11, 2026
- September 11, 2026
- September 10, 2026
- September 10, 2026
- September 8, 2026
- September 3, 2026Other event 8-K
What is TEVA worth? A DCF from its reported cash flow
Insider trades
What the people running Teva Pharmaceutical Industries Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $17M worth of shares in the last 90 days and bought none on the open market. 12% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Mignone RobertoDirector | Soldindirect | 367,600 | $14.4M |
| September 18, 2026 | Savage BrianInterim Chief Legal Officer | Exercised options | 4,503 | $156.3K |
| September 18, 2026 | Savage BrianInterim Chief Legal Officer | Sold | 4,503 | $174.2K |
| September 18, 2026 | Savage BrianInterim Chief Legal Officer | Sold | 2,525 | $98.8K |
| September 18, 2026 | Savage BrianInterim Chief Legal Officer | Sold | 314 | $12.2K |
| August 21, 2026 | Satchi-Fainaro RonitDirector | Sold | 415 | $15.5K |
| August 21, 2026 | Weiss AmirChief Accounting Officer | Sold | 6,945 | $261.2K |
| August 21, 2026 | Weiss AmirChief Accounting Officer | Exercised options | 2,500 | $49K |
| August 21, 2026 | Weiss AmirChief Accounting Officer | Sold | 2,500 | $94.1K |
| August 17, 2026 | Lippman EvanEVP, Business Development | Soldpre-planned (10b5-1) | 18,600 | $680.3K |
| August 5, 2026 | Zaks Tal ZviDirector | Sold | 17 | $592.7 |
| August 3, 2026 | Hughes Eric ASee "Remarks" | Exercised options | 52,744 | - |
| August 3, 2026 | Hughes Eric ASee "Remarks" | Soldpre-planned (10b5-1) | 25,578 | $892.1K |
| August 3, 2026 | Jover PlacidSee "Remarks" | Exercised options | 12,827 | - |
| August 3, 2026 | Jover PlacidSee "Remarks" | Soldpre-planned (10b5-1) | 12,827 | $447.4K |
Who owns TEVA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Harel Insurance Investments & Financial Services Ltd13G, passive | 6.3% | February 9, 2026 |
| Migdal Insurance & Financial Holdings Ltd13G, passive | 5.37% | February 17, 2026 |
| Menora Mivtachim Holdings Ltd13G, passive | 5% | July 17, 2025 |
| Phoenix Financial Ltd.13G, passive | 5% | July 22, 2025 |
Largest institutional holders
Insiders
19 insiders reported holding 4,900,622 shares in total, about $190.5M at the last price.
| Holder | Shares |
|---|---|
| Elstein AmirDirector | 2,118,455 |
| Francis Richard DPresident and CEO | 1,177,529 |
| Barer Sol JDirector | 448,011 |
| Hughes Eric ASee "Remarks" | 134,877 |
| Lieberman Gerald MDirector | 130,149 |
| Crane Rosemary ADirector | 127,739 |
| Nisen PerryDirector | 119,807 |
| Mignone RobertoDirector | 119,807 |
| Satchi-Fainaro RonitDirector | 111,986 |
| Sabag MarkSee "Remarks" | 80,760 |
Questions about TEVA
What does Teva Pharmaceutical Industries Ltd do?
Teva Pharmaceutical Industries develops, produces, and markets generic pharmaceuticals, active pharmaceutical ingredients, and specialty medicines. The company supplies prescription drugs, over-the-counter treatments, and sterile injectables to healthcare systems, pharmacies, and hospitals worldwide. Its shares trade on NYSE under the ticker TEVA.
How much revenue does Teva Pharmaceutical Industries Ltd make?
Over the twelve months to June 30, 2026 Teva Pharmaceutical Industries Ltd reported revenue of $14.1B. That is 15.2% less than a year earlier.
When did Teva Pharmaceutical Industries Ltd last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.
Similar companies
Compare TEVA with
Follow TEVA
Get an email when Teva Pharmaceutical Industries Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow TEVA: get an email when it filesWhere the numbers come from
Financial figures are the values Teva Pharmaceutical Industries Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.